Related Experiment Videos
Cellular suicide therapy of malignant disease
C J Link1, T Seregina, A Traynor
1Northwestern University School of Medicine and The Robert H. Lurie Cancer Center, Chicago, Illinois, USA.
Stem Cells (Dayton, Ohio)
|June 7, 2000
Summary
Adoptive cellular therapy using genetically modified cells shows promise for treating leukemia and ovarian cancer. Early trials indicate antitumor responses, though further research is needed for broader application.
Area of Science:
- Oncology
- Immunotherapy
- Gene Therapy
Background:
- Adoptive cellular therapy is an emerging cancer treatment.
- Allogeneic donor lymphocyte infusions (DLI) can treat hematologic malignancies but cause graft-versus-host-disease.
- Xenogeneic cellular therapy offers an alternative approach.
Purpose of the Study:
- To evaluate genetically altered allogeneic and xenogeneic cellular therapies for cancer treatment.
- To assess the safety and efficacy of suicide gene-modified DLI for leukemia.
- To investigate xenogeneic fibroblast cells delivering a suicide gene for ovarian cancer.
Main Methods:
- Genetically modified allogeneic lymphocytes with a suicide gene for leukemia treatment.
- Genetically modified xenogeneic fibroblast cells delivering a tumor-directed cytotoxic gene for ovarian cancer.
- Utilized retroviral vectors for gene transduction into tumor cells.
Main Results:
- Early clinical trials show evidence of antitumor responses in some patients.
- Modified DLI aims to mitigate graft-versus-host-disease toxicity.
- Xenogeneic cells selectively target replicating tumor cells for ganciclovir-mediated killing.
Conclusions:
- Allogeneic and xenogeneic adoptive cellular therapies represent early-stage cancer treatments.
- Limited but encouraging antitumor responses observed in initial trials.
- Further advances in basic science and vector technology are necessary for wider clinical use.